Nova Oculus has developed a non-invasive electro-therapeutic device that utilizes microcurrent technology to stimulate retinal function and enhance nutrient transport in patients with dry age-related macular degeneration. This treatment addresses the lack of effective therapies for this condition, offering measurable improvements in vision for those affected.
Funding
Funding not disclosed
Founders
Product
Problem
Dry age-related macular degeneration (AMD) lacks effective therapies, leading to progressive vision loss due to retinal dysfunction and impaired nutrient transport. Current treatments offer limited benefits, leaving a significant unmet need for interventions that can improve visual outcomes for affected individuals.
Solution
Nova Oculus has developed the Nova Oculus III, a non-invasive electro-therapeutic medical device that utilizes microcurrent technology to stimulate retinal function and enhance nutrient transport in patients with dry AMD. The device delivers a range and pattern of frequencies designed to stimulate a physiological response at the retinal level. This microcurrent stimulation aims to boost the production of Adenosine Triphosphate (ATP), an active transport enzyme, which facilitates the movement of nutrition from the blood to the retinal cells. Treatment with the Nova Oculus III is drug-free and intended to provide measurable improvements in vision.
Target Audience
The primary target audience includes individuals diagnosed with dry age-related macular degeneration (AMD) and eye care professionals, such as optometrists and ophthalmologists, seeking effective therapeutic interventions for their patients.
Features
- Non-invasive microcurrent stimulation of the retina
- Specifically designed waveforms to target retinal structures
- Stimulation of Adenosine Triphosphate (ATP) production to enhance nutrient transport
- Lightweight and easy-to-use design for patient comfort
- Demonstrated efficacy in clinical trials with measurable improvements in vision